Nine- to Twelve-Month Anti-Tuberculosis Treatment Is Associated with a Lower Recurrence Rate than 6–9-Month Treatment in Human Immunodeficiency Virus-Infected Patients: A Retrospective Population-Based Cohort Study in Taiwan

Abstract

BackgroundHuman immunodeficiency virus (HIV)-infected patients are at an increased risk of tuberculosis (TB) and its recurrence following completion of anti-TB treatment. We investigated whether extending anti-TB treatment to 9 months or longer reduces TB recurrence.MethodsHIV-infected patients who were diagnosed with pulmonary TB between 1997 and 2009 and who received anti-TB treatment for a duration between 5.5 and 12.5 months were identified from the National Health Insurance Research Database in Taiwan. Those who received any non-fluoroquinolone second-line anti-TB drug for >28 days were excluded. Factors associated with TB recurrence within 2 years after completion of anti-TB treatment were explored using Cox regression analysis. Sensitivity analysis was performed for a subpopulation fulfilling strict diagnostic criteria for HIV infection.ResultsTB recurrence was observed in 18 (3.5%) of 508 HIV-infected patients. The recurrence rate declined from 5.4% to 1.0% after the implementation of directly observed therapy, short course (DOTS) in 2006 (p = 0.014). The recurrence rate was 5.9%, 5.2%, and 1.6% in patients who received anti-TB treatment for <195, 195–270, and >270 days, respectively (p = 0.066). Cox regression analysis revealed that TB diagnosed in the DOTS era (hazard ratio [HR]: 0.18 [0.04–0.77]) and anti-TB treatment for >270 days (HR: 0.24 [0.06–0.89]) were associated with a reduced risk of TB recurrence. Sensitivity analysis of 449 selected patients revealed that anti-TB treatment for >270 days was a significant factor.ConclusionIn Taiwan, the 2-year TB recurrence rate in HIV-infected patients declined after implementation of DOTS. The risk of TB recurrence in HIV-infected patients can be further reduced by extending anti-TB treatment to 9–12.5 months.

Recent updates on drug resistance in Mycobacterium tuberculosis

“…The new guidelines recommend shorter, standardized 9–12 months treatment regimen in patients with RR/MDR‐TB (Wang et al . ; Falzon et al ). The grouping of the drugs used for the treatment of MDR/RR‐TB and XDR‐TB is revised by GDG based on the updated evidence reviews on their effectiveness and safety (World Health Organization ).…”

Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan

“…Risk factors for TB development among contacts are also not well defined [ 2 ]. To expand current understanding and knowledge of TB contact investigation, we recruited a population-based TB contacts cohort utilising the National Health Insurance Research Database of Taiwan, which included medical care claims data of 99% Taiwan residents [ 7 ].…”

Acute biliary events during anti-tuberculosis treatment: hospital case series and a nationwide cohort study

“…Comorbid conditions—comprising diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), malignancy, end-stage renal disease, connective tissue disease, acquired immunodeficiency syndrome, liver cirrhosis, transplantation, pneumoconiosis, and low-income status—at the time TB diagnosis were identified by using previously published definitions [ 9 , 10 ].…”